Gary, If NWBO has statistically significant results, it will immediately capture global attention. (Les showed what media he could actually line up when the JTM paper was published) Every researcher in cancer knows about this trial. Most have written it off in their gut, probably because it offers so much promise yet so many dendritic trials have failed. NWBO has already been a one billion market cap. The market cap is, imo, what one pays attention to. If statistically significant results are reached, this market cap could easily rise to 5 billion (or much higher) before any offer has a chance to be technically made (that's around $5 (or more) per share).
A 350% increase from 5 = 22.5.
News 
Market Data 
Discover 
